Atara Biotherapeutics Submits Tabelecleucel (Tab-cel®)

First Allogeneic T-Cell Therapy BLA Submission to U.S. Food and Drug Administration


If Approved, Tab-cel Would be First Approved Therapy in U.S. for EBV+ PTLD


Acceptance of BLA Will Trigger $20...

Related Keywords

California , United States , Ukraine , Denver , Colorado , Pascal Touchon , Pierre Fabre , Securities Exchange , Linkedin , Memorial Sloan Kettering Cancer Center , Atara Biotherapeutics Inc , Exchange Commission , Drug Administration , Nasdaq , Biologics License Application , Chief Executive Officer , Objective Response Rate , Securities Act , Securities Exchange Act , Pierre Fabre Laboratories , Middle East , Southern California , Financial Condition ,